|Videos|June 6, 2017

C. difficile Tends to Be Over-Diagnosed in Healthcare Facilities

Niaz Banaei, MD, discusses some reasons why healthcare-associated C. difficile tends to be over-diagnosed.

Niaz Banaei, MD, Associate Professor, Pathology, Stanford University, discusses some reasons why healthcare-associated C. difficile tends to be over-diagnosed.

Interview Transcript (slightly modified for readability)

“[Clostridium] difficile colonization is quite common in patients [who] are entering hospitals and patients [who] are [already] hospitalized. These patients are then exposed to a number of reasons to develop nosocomial diarrhea, such as: they get antibiotics, chemotherapy, radiation, laxatives, and medications that induce diarrhea.

Then we look for Clostridium difficile as a cause of diarrhea in these patients. If they test negative, that’s easy; we assume that they don’t have C. diff infection, but if they test positive, we diagnose them as C. diff infection. In reality, a fraction of these patients are diagnosed with colonization, but given the diagnosis of infection. Almost all of these patients end up getting treated for C. diff infection, and, therefore, we are over diagnosing C. diff in a fraction of these patients.”


Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: XDR Shigella
Here is some important information around this pathogen and the intestinal infection.